LB
Lyudmila Bazhenova
University of California San Diego
Research areas: Medicine · Pulmonary and Respiratory Medicine · Lung Cancer Treatments and Mutations · Lung Cancer Diagnosis and Treatment · Cancer Genomics and Diagnostics
0000-0001-8764-4359
Employment
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (121)
- Characterizing Time Toxicity in Lung Cancer Clinical Trials: Development and Application of a Novel Time Burden Metric Save
- Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1 Save
- Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0 Save
- Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study Save
- Circulating Biomarkers and Targeted Therapy in Pleural Mesothelioma Save
- Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status Save
- Second line advanced or metastatic non-small cell lung cancer treatment after chemo-immunotherapy: a retrospective study Save
- Treatment of Pleural Mesothelioma: ASCO Guideline Update Save
- Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2 Save
- Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study Save
- Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma Save
- Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome Save
- Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial Save
- Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial Save
- Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial Save
- Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial Save
- Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial Save
- Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial Save
- Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG) Save
- Data from A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer Save